A Randomized Placebo Controlled Study of OSI-774 (Erlotinib HCl, Tarceva[TM]) in Patients With Incurable Stage IIIB/IV Non-small Cell Lung Cancer Who Have Failed Standard Therapy for Advanced or Metastatic Disease
A Randomized Placebo Controlled Study of OSI-774 (Erlotinib HCl, Tarceva[TM]) in Patients With Incurable Stage IIIB/IV Non-small Cell Lung Cancer Who Have Failed Standard Therapy for Advanced or Metastatic Disease
The purpose of this study is to determine if OSI-774 will improve overall survival of patients with incurable stage IIIB/IV non-small cell lung cancer compared to standard of care. OSI-774 is a new type of drug under evaluation called an epidermal growth factor receptor (EGFR). OSI-774 is an investigational drug that has not yet been approved by the U.S. Food and Drug Administration (FDA).
Capital Federal, CP1417, Argentina
Capital Federal, Argentina
Woden, Australian Capital Territory 2605, Australia
South Australia, 5000, Australia
Victoria, 3002, Australia
Victoria, 3084, Australia
Missisauga, Ontario L5M 2N1, Canada
Saint Catherines, Ontario L2R 5K3, Canada
Sault Saint Marie, Ontario P6A 2C4, Canada
Ste-Foy, Quebec G1V 4G5, Canada
Hermer, 58675, Germany
Petach-Tiqva, 49100, Israel
Petach-Tiqva, 49372, Israel
Riddiford Street, Wellington Region, New Zealand
Westbridge, Durban 4091, South Africa
Parklands, 2121, South Africa
Phayathai, Bangkok 10400, Thailand